Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Lung Penetration of Ceftolozane/Tazobactam in Critically Ill Patients
NCT02387372Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of ceftolozane + tazobactam in bacterial pneumonia (2 arms), sponsored by Merck & Co. Primary endpoints: Maximum Plasma Concentration at Day 2, Epithelial Lining Fluid / Plasma Ratio at Day 2 and 8 more. Started Feb 2015; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
bacterial pneumonia
Beyond the preview
Go deeper on NCT02387372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387372.